Activity: 2025 Chinese Medical Enterprises to Shai Australia Station

Background Introduction

January 2024, China's [medical enterprise overseas authorization] transaction amount reached $9.146 billion. The popularity of the transaction highlights the international market's recognition of the ability of domestic innovative pharmaceutical companies, and 2024 will become the first year of explosive growth in China's [pharmaceutical going to sea].
Compared with Europe and North America, which have mature patented technology and production processes and production capacity, Australia and New Zealand can only rely on foreign imports. In 2022, Australia's medical device imports will be about 4.8 billion Australian dollars, mainly from the United States, Germany and China; in 2022, Australia's drug imports will be about 19 billion Australian dollars, accounting for more than 70% of the Australian drug market, mainly from the United States, the United Kingdom, Switzerland and other countries. Mainly patented drugs. China has a mature production intelligent manufacturing industry chain, "going out and bringing in" is the only way for many enterprises to develop in the future.
Australia's per capita income ranks among the top five in the world, and its human development index ranks second in the world. Australia is a biomedical powerhouse, with eight Nobel Prize winners in Physiology or Medicine, a well-developed health care system, a well-established regulatory review mechanism and strong research transformation capabilities, [world-class research infrastructure] comparable to those of the United States, and its clinical research capabilities have reached international standards, with the Australian government providing up to 43.5 per cent of [supportive R & D tax rebates] for clinical research. It is certified by the Australian Medicines Agency (TGA) and can be recognized by the same PIC/S member countries as Australia, including more than 20 countries including the United Kingdom, France, Germany, Italy, Canada, Singapore and the Netherlands.

preemptive

Visiting guests

Australian Medicines Agency (TGA) Specialist
Australian government officials
University of Sydney, University of Technology Sydney, Macquarie University and other scientific research institutions experts and scholars
Head of Public and Private Hospitals in Australia
Australian pharmaceutical company CEO
General Manager of Investment M & A
Australian CRO Company Representative
Australian Chinese Medicine Association, Australian Chamber of Commerce Overseas Chinese Leader
Pharmacy Channel Leader, Pharmacist,
Australia Medical Devices and Medical Consumables Agents
Commonwealth Bank of Australia Commercial Loan Manager, Australian Barrister, Certified Public Accountant
Head of International Logistics Enterprise
Australian English and Chinese mainstream media journalists

dialogue and exchange

clinical trials should choose Australia and how to apply for the R & D refund scheme
TGA's Market Access Requirements and Certification Management for Drugs and Medical Devices
Compliance Review of GMP Regulations and Listed Drugs
Australian Biotechnology and Clinical Trials Program Service Solutions
Deciphering the Australian Medical Investment and M & A Code
Australian universities collaborate on research and development projects in the field of medicine and health
Australian Market (ASX) Listing Conditions and Advantages
New Opportunities and New Strategies for Chinese Medical Enterprises Going to Sea

take advantage of the situation

Australian General Practice Conference and Exhibition GPCE--
It is the professional exhibition of the medical industry, attracting the largest number of general practitioners, nurses, medical equipment manufacturers, pharmaceutical manufacturers, rehabilitation equipment manufacturers, medical insurance companies and other professionals in Australia and around the world each year, showcasing the latest medical products, treatments and innovations related to general medicine and primary care. GPCE also offers a series of seminars and forums that provide exhibitors and visitors with the latest insights, experiences and knowledge of the healthcare industry, as well as the opportunity to learn about market trends and technological innovations.

Itinerary Highlights Six Days and Five Nights

day to participate in the Australian general medicine conference and exhibition exchange
New South Wales Parliament House Breakfast Meeting with Australian Parliamentarians and Government Officials
Visit to TGA-certified Australian healthcare companies
Visit the University of Sydney or University of Technology Sydney, Macquarie University Medical School Laboratory
Visit to Australian hospitals and pharmacies
Visit to Australian medical product suppliers
Australian company registration, tax refund and listing
Australian Commercial Bank Lending Policy
Medical Project Docking/Entrepreneur Roundtable Dialogue

Sydney itinerary